Body of work: Long-awaited IPO nears for promising biotech firm

From surgical training to high school dissection labs, SynDaver has charted a clear-cut course for its synthetic human and animal products. A payoff for investors could be in the offing.

  • By Brian Hartz
  • | 6:00 a.m. January 24, 2020
  • | 0 Free Articles Remaining!
Mark Wemple. Over the past 15 years, SynDaver founder and CEO Dr. Christoper Sakezles has guided the biotech firm to the brink of what could be a lucrative IPO.
Mark Wemple. Over the past 15 years, SynDaver founder and CEO Dr. Christoper Sakezles has guided the biotech firm to the brink of what could be a lucrative IPO.
  • Strategies
  • Share

SynDaver, the Tampa biotech firm that makes incredibly lifelike artificial humans and animals — most recently a fake frog used in biology class dissections — has long talked of going public. More than four years ago, 2018 was touted as the year Wall Street would welcome it to the party.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • February 3, 2026
St. Petersburg Gas Plant RFP draws nine proposals
  • February 3, 2026
DeSantis, MLB commissioner support Tampa Bay Rays' stadium plans
  • February 3, 2026
California hedge fund makes $1.1B offer to buy MarineMax
  • February 3, 2026
Landmark downtown Sarasota hotel torn down for new project

Sponsored Content